Yazar "Ahmadi, Seyed Sajad" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules
    (Springer Basel Ag, 2025) Afshari, Amir R.; Sanati, Mehdi; Aminyavari, Samaneh; Keshavarzi, Zakieh; Ahmadi, Seyed Sajad; Oroojalian, Fatemeh; Karav, Sercan
    Glioblastoma multiforme (GBM), the fatal primary brain malignancy in adults, represents significant health challenges, and its eradication has been the ultimate goal of numerous medical investigations. GBM therapy encompasses various interventions, e.g., chemotherapy by synthetic cytotoxic agents like temozolomide (TMZ), radiotherapy, and, more recently, immunotherapy. A notable focus has been on incorporating naturally occurring substances in treating malignancies. Polyphenols and terpenoids, widely present in fruits and vegetables, constitute primary categories of agents employed for this purpose. They pose direct and indirect impacts on tumor growth and chemoresistance, mainly through impacting the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling, crucial in cellular processes, metabolism, and programmed death. This paper thoroughly discusses the biologic effects and practical application of polyphenols and terpenoids on GBM through the PI3K/Akt/mTOR signaling in vitro and in vivo.
  • [ X ]
    Öğe
    Harnessing the role of insulin-like growth factor in glioblastoma: a comprehensive review
    (Pergamon-Elsevier Science Ltd, 2026) Nakhaei, Ali; Afshari, Sadaf; Mohammadian, Mohammad; Ahmadi, Seyed Sajad; Mohatshami, Elmira; Jalili-Nik, Mohammad; Jalali, Mahsa
    This review provides an overview of the biological function of the insulin-like growth factor (IGF) system in glioblastoma (GB) development and a thorough examination of its therapeutic relevance. Networks of micro-RNAs regulated by insulin-like growth factor 1 (IGF-1) that impede GB's response to temozolomide (TMZ). The amounts of PDGFR, IGF1R, PI3K, and ERK1/2 proteins and their potential as therapeutic targets. Anti-epidermal growth factor receptor (EGFR) agents may encounter significant resistance from IGF-R inhibitors that operate via PI3K signaling pathways. Insulin-like growth factor-binding protein (IGFBP)-2 modulates CD24, hence increasing the invasiveness of GB cells. 5) Due to the proliferation, invasion, and chemotherapy resistance of GB cells when exposed to exogenous IGFBP-2, targeting the integrin beta 1/ERK signaling pathway may serve as an effective therapeutic strategy for GB treatment. The IGFBP-2/integrin/ILK/NF-kappa B network functions as a biologically active signaling pathway in vivo, facilitating the proliferation of GB. Activation of the Hedgehog (HH) pathway and overexpression of the downstream effector GLII accelerate glioma tumorigenicity and the biology of glioma stem cells (GSCs). The aggressive nature of gliomas is attributed to PTEN failure and elevated levels of IGFBP-2 expression. IGFBP-2 augments the expression of CD144 and MMP2, promoting the development of vasculogenic mimicry (VM) in GB cells. Recent investigations have revealed a crucial signaling mechanism that is vital for the survival of GB patients.